Dr. Reddy's Laboratories Limited (BOM:500124)
India
· Delayed Price · Currency is INR | Market Cap | 963.46B |
| Revenue (ttm) | 325.54B |
| Net Income (ttm) | 56.54B |
| Shares Out | 833.15M |
| EPS (ttm) | 67.78 |
| PE Ratio | 17.06 |
| Forward PE | 17.11 |
| Dividend | 8.00 (0.69%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 113,089 |
| Average Volume | 75,974 |
| Open | 1,130.05 |
| Previous Close | 1,148.70 |
| Day's Range | 1,130.05 - 1,166.25 |
| 52-Week Range | 1,025.90 - 1,420.20 |
| Beta | 0.34 |
| RSI | 47.87 |
| Earnings Date | May 9, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript
Dr Reddy’s Q4 PAT up 22%
Hyderabad: Dr Reddy's Laboratories posted a consolidated 22% jump in profit after tax attributable to equity holders at Rs 1,594 crore for the fourth .
Dr. Reddy's Q4 & Full Year FY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.
Dr Reddy’s Q4 net profit rises 21% to Rs 1,587 crore on strong global sales
Dr. Reddy's Laboratories announced a 21% surge in net profit, reaching Rs 1,587 crore for the March 2025 quarter, fueled by strong sales in the US and India. Annual profit saw a modest 3% rise to Rs 5...
Earnings calendar for May 9: ABB, Dr Reddy’s, Bank of India, Manappuram, Thermax among key firms to report Q4 results
A busy earnings day is lined up for Thursday, May 9, as several major and mid-sized Indian companies are scheduled to report their financial results for the fourth quarter of FY25. The announcements a...
Dr. Reddy's Q4 Earnings Preview
Dr Reddys eyes global GLP-1 market with generic drug rollout on patent expiry
Hyderabad: Dr Reddy's Laboratories is positioning itself to enter the lucrative GLP-1 (glucagon-like peptide-1) drug market, with plans to launch gene.
Nifty 50 top gainers today, April 24: IndusInd Bank, UltraTech Cement, Grasim Industries, Dr. Reddy’s and more
Indian equity markets ended lower on April 24, with both key indices, the Sensex and Nifty 50, closing in the red. The Sensex dropped 315.06 points, or 0.39%, settling at 79,801.43, while the Nifty 50...
Dr Reddy’s shares jump over 2% as Nuvama reiterates ‘Buy’ with Rs 1,533 target; company denies layoff report
Shares of Dr Reddy’s Laboratories rose over 2% to ₹1,135.30 in early trade on Monday, April 15, after the company firmly denied a media report alleging workforce cost cuts amid pressure on Revlimid ma...
Pharma co Dr Reddy's to reduce costs
India-Business News: HYDERABAD: Even as the threat of US tariffs on pharma imports looms large, Dr Reddy's Laboratories is wielding the axe to cut flab and lower costs. It.
'Factually incorrect': Dr. Reddy clears air amid workforce reduction rumors
Dr. Reddy's Laboratories has refuted media reports alleging a 25% reduction in workforce costs. The Hyderabad-based pharmaceutical giant dismissed claims of layoffs targeting high-earning employees an...
Dr. Reddy’s denies report of 25% workforce cost cut amid Revlimid margin strain
Dr. Reddy’s Laboratories Ltd. has firmly denied a recent media report alleging that the company has cut workforce costs by 25% amid margin pressure linked to Revlimid. In a regulatory filing to the st...
Dr Reddy’s initiates 25% workforce reduction, report suggests
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...
Dr Reddy’s shares fall 4% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Dr Reddy’s Laboratories saw its stock decline by 4% after U.S. President Donald Trump signaled plans to impose tariffs on pharmaceutical imports. Speaking at a National Republican Congressional Commit...
Pharma stocks reel under pressure: Biocon plunges 5.64%, IPCA Labs slips 4.67%, Glenmark down 3.56%; Torrent Pharma lone gainer
Pharmaceutical stocks witnessed heavy selling pressure in early trade on Monday, dragged down by broader market weakness amid rising global trade tensions. At 9:28 AM, benchmark indices Sensex and Nif...
Stocks to watch today: Tata Motors, ITC, Dr. Reddy’s, IndusInd Bank, L&T, Biocon, Indusind Bank, Astra Zenecca in focus
Indian stock markets are set to react to a slew of corporate announcements and macro developments on Monday, with several major and midcap companies in the spotlight. Tata Motors will likely be under ...
Dr. Reddy’s Laboratories: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern
Dr. Reddy’s Laboratories Limited, a Hyderabad-based global pharmaceutical company, is a key player in India’s healthcare sector. As of April 05, 2025, Dr. Reddy’s is recognized for its extensive portf...
Pharma sector: High US exposure puts Indian pharma stocks like Natco, Aurobindo, Dr Reddy’s, Lupin on edge amid Trump tariff threat
As the Trump administration intensifies its trade stance with the unveiling of fresh tariff threats, Indian pharmaceutical companies with high US revenue exposure have come under the spotlight. The ph...
Dr Reddy’s shares surge 5% as Trump exempts pharma exports from reciprocal tariff
Shares of Dr Reddy’s Laboratories jumped 5% on April 3 after the U.S. administration confirmed that pharmaceutical products would be exempt from the newly imposed 26% reciprocal tariff on Indian goods...
Pharma stocks surge as Trump tariffs spare sector; Aurobindo (+8.1%), Dr Reddy’s (+6.2%), Lupin (+4.9%) lead rally on tariff relief
Indian pharma stocks were among the top gainers on Thursday morning after the sector was excluded from the newly announced reciprocal tariffs by the Trump administration. The sharp rally reflects reli...
Pharma stocks like Zydus Life, Lupin, Aurobindo Pharma, Dr Reddy’s Lab to rally as Trump exempts tariffs on pharma for now
Pharma stocks are poised for a relief rally after US President Donald Trump exempted the pharma sector from tariffs.
Sun Pharma, Dr. Reddy’s, Welspun India, Bharat Forge, Lupin, Biocon, UPL, Aurobindo, Indo Count, Cummins India and over 100 other Indian companies could face major impact from 26% US tariff hike
In a major escalation of trade tensions, US President Donald Trump on April 2 announced a 26% reciprocal tariff on imports from India, citing high tariffs imposed by India on American goods. The move ...
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative th...